Why the study?
Clinical use of anthracyclines is limited by severe cardiotoxicity, prompting a need to summarize and update emerging mechanisms across cellular levels and explore targeted therapeutic approaches.
What are the cellular and structural mechanisms underlying anthracycline-induced cardiotoxicity?
Design
Review
Authors
Loading...
May inform future cardioprotective strategies; extends mechanistic framework but leaves clinical translation open.
What are the cellular and structural mechanisms underlying anthracycline-induced cardiotoxicity?
This review provides an updated overview of the cellular and structural mechanisms driving anthracycline-induced cardiotoxicity, highlighting potential therapeutic targets.
Li et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: